Johnson & Johnson has withdrawn its controversial vaginal mesh product from the Australian market after missing a deadline requiring all such products to carry warnings of potential side-effects
Amicus Therapeutics has received the Australian Therapeutic Goods Administration (TGA) approval for Galafold (Migalastat) to treat patients with Fabry disease (alpha-galactosidase A deficiency) in the country.